Payment overview · 2025
General Payments
$588.37
33 reported records · 8 companies
Healthcare provider profile · identity verified
Heather D Rowe, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1427066489
Verified facts
What the public records show
CMS Open Payments records show Heather D Rowe, MD received $588.37 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $194.28 | 33.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.23 | 26.4% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.75 | 11.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.10 | 9.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.35 | 7.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.10 | 5.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.25 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.31 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $588.37 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $155.23 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $127.27 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $125.87 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.13 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.01 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $64.75 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.10 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 158 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
158 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 430 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 317 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 285 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 71 |
| Lisinopril | Lisinopril | 221 | 62 |
| Losartan Potassium | Losartan Potassium | 215 | 64 |
| Metformin Hcl | Metformin Hcl | 169 | 56 |
| Montelukast Sodium | Montelukast Sodium | 166 | 44 |
| Ozempic | Semaglutide | 158 | 37 |
| Omeprazole | Omeprazole | 147 | 44 |
| Gabapentin | Gabapentin | 125 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 28 |
| Sertraline Hcl | Sertraline Hcl | 116 | 25 |
| Jardiance | Empagliflozin | 112 | 26 |
| Carvedilol | Carvedilol | 110 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 36 |
| Alendronate Sodium | Alendronate Sodium | 96 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 28 |
| Synthroid | Levothyroxine Sodium | 79 | 22 |
| Prednisone | Prednisone | 77 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 27 |
| Spironolactone | Spironolactone | 75 | 26 |
| Valacyclovir | Valacyclovir Hcl | 75 | 27 |
| Trazodone Hcl | Trazodone Hcl | 74 | 15 |
| Xarelto | Rivaroxaban | 72 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 18 |
| Famotidine | Famotidine | 67 | 24 |
| Cefdinir | Cefdinir | 64 | 52 |
| Valsartan | Valsartan | 64 | 20 |
| Meloxicam | Meloxicam | 63 | 22 |
| Topiramate | Topiramate | 63 | suppressed |
| Alprazolam | Alprazolam | 62 | 22 |
| Ezetimibe | Ezetimibe | 61 | 20 |
| Donepezil Hcl | Donepezil Hcl | 59 | 13 |
| Potassium Chloride | Potassium Chloride | 59 | 23 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Eliquis | Apixaban | 57 | 17 |
| Furosemide | Furosemide | 57 | 21 |
| Memantine Hcl | Memantine Hcl | 56 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 18 |
| Tramadol Hcl | Tramadol Hcl | 55 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 20 |
| Allopurinol | Allopurinol | 54 | 17 |
| Progesterone | Progesterone, Micronized | 54 | 16 |
| Bupropion Xl | Bupropion Hcl | 53 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 17 |
| Fluconazole | Fluconazole | 52 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 15 |
| Dexamethasone | Dexamethasone | 51 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 16 |
| Celecoxib | Celecoxib | 50 | 11 |
| Torsemide | Torsemide | 50 | 18 |
| Lorazepam | Lorazepam | 48 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 15 |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 45 | 12 |
| Metformin Hcl Er | Metformin Hcl | 44 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Estradiol | Estradiol | 37 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 12 |
| Simvastatin | Simvastatin | 37 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 18 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 33 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 11 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 13 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | 11 |
| Naproxen | Naproxen | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Acyclovir | Acyclovir | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Easy Comfort Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $588.37 · 33 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, COMIRNATY, EVENITY, FREESTYLE LIBRE 3, MOUNJARO, Ozempic, PREVNAR 20, PROLIA, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error